Efficacy of Continuing SGLT2 Inhibitors on Outcomes in Patients with Acute Decompensated Heart Failure

Sodium-glucose cotransporter 2 inhibitor (SGLT2i) reduces mortality and morbidity in patients with chronic heart failure (HF). However, the clinical implication of SGLT2i therapy acute decompensated HF remains uncertain. We prospectively studied 86 type diabetic mellitus (T2DM) (71.8 ± 12.1 years, 55 men) who were hospitalized for received during index hospitalization. Among patients, 56 continued at discharge 30 did not. The group experienced fewer re-hospitalizations than discontinued (24% versus 39%, P = 0.008) a hazard ratio 0.29 (95% confidence interval 0.10-0.85) adjusted other significant potential confounders. In conclusion, long-term might prevent unplanned re-hospitalization T2DM HF.